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Skeletal muscle insulin resistance is a major characteristic of obesity and type 2 diabetes. Although obesity-mediated inflamma-
tion is causally associated with insulin resistance, the underlying mechanism is unclear. Here, we examined the effects of chronic
obesity in mice with muscle-specific overexpression of interleukin-10 (MIL10). After 16 weeks of a high-fat diet (HFD), MIL10 mice
becamemarkedly obese but showed improved insulin action compared to that of wild-type mice, which was largely due to in-
creased glucose metabolism and reduced inflammation in skeletal muscle. Since leptin regulates inflammation, the beneficial
effects of interleukin-10 (IL-10) were further examined in leptin-deficient ob/obmice. Muscle-specific overexpression of IL-10 in
ob/obmice (MCK-IL10ob/ob) did not affect spontaneous obesity, but MCK-IL10ob/ob mice showed increased glucose turnover
compared to that in ob/obmice. Last, mice with muscle-specific ablation of IL-10 receptor (M-IL10R/) were generated to de-
termine whether IL-10 signaling in skeletal muscle is involved in IL-10 effects on glucose metabolism. After an HFD,
M-IL10R/mice developed insulin resistance with reduced glucose metabolism compared to that in wild-type mice. Overall,
these results demonstrate IL-10 effects to attenuate obesity-mediated inflammation and improve insulin sensitivity in skeletal
muscle, and our findings implicate a potential therapeutic role of anti-inflammatory cytokines in treating insulin resistance and
type 2 diabetes.
Obesity has emerged as a global issue in recent decades and isassociated with numerous human diseases, including insulin
resistance, type 2 diabetes, and cardiovascular diseases (1, 2). The
underlying mechanism by which obesity induces numerous
health problems remains poorly understood. In that regard, in-
creasing evidence suggests an important role of a dysregulated
immune system in obesity-mediated insulin resistance (3, 4).
Obesity is characterized by altered levels of circulating cytokines,
and adipose tissue macrophage accumulation and inflammation
have been causally associated with insulin resistance (5, 6). How-
ever, recent studies have challenged this earlier notion on the
causal role of adipose tissuemacrophages and inflammation in the
development of insulin resistance (7, 8).
While adipose tissue is widely viewed as the epicenter of obe-
sity-mediated inflammation, it is not the only organ shown to
develop macrophage infiltration and inflammation in obesity. In
fact, recent studies indicate that obesity-mediated inflammation
and macrophage accumulation develop in multiple organs, in-
cluding skeletalmuscle, liver, pancreas, heart, and brain (9–13). In
that regard, our recent study found that exercise-mediated weight
loss improved insulin action without affecting adipose tissue in-
flammation in mice with diet-induced obesity (7). Additionally,
improved insulin action following weight loss was associated with
reduced local inflammation in skeletal muscle, suggesting an im-
portant role of muscle inflammation in obesity-mediated insulin
resistance (7). These findings clearly contest the adipocentric view
of insulin resistance.
Interleukin-10 (IL-10) is a Th2-type cytokine that inhibits the
synthesis and activity of proinflammatory cytokines and counter-
acts Toll-like receptor-mediated inflammation (14–16). We have
previously shown that transgenic overexpression of IL-10 selec-
tively in skeletal muscle improved glucose metabolism in mice
after 3 weeks of a high-fat diet (HFD) (9).While our previous data
suggest a potential therapeutic role of IL-10 in type 2 diabetes, our
interpretation is limited due to the short-term feeding of an HFD
not resulting inmice having developed type 2 diabetes phenotypes
(i.e., hyperglycemia). Therefore, the current studywas designed to
specifically examine the role of IL-10 in markedly obese and dia-
betic mice after 16 weeks of an HFD (chronic HFD), a better
representation of obese type 2 diabetic human subjects. Addition-
ally, leptin is an important adipocyte-derived hormone that is
elevated in obesity and regulates numerous physiological func-
tions, including energy balance and inflammation (17). Thus, the
present study also examined the effects of muscle-specific trans-
genic expression of IL-10 on glucose metabolism in leptin-defi-
cient ob/ob mice. Last, we examined whether IL-10 signaling in
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skeletal muscle is directly responsible for IL-10 effects on muscle
glucosemetabolismusing a newly generatedmousemodel lacking
the IL-10 receptor 1 type chain selectively in skeletal muscle. Our
findings indicate that selective targeting of IL-10 signaling in skel-
etal muscle improves glucose metabolism in obese and diabetic
mice following a chronic HFD or with a deficiency in leptin and
further demonstrate that these effects are mediated by direct acti-
vation of IL-10 signaling in skeletal muscle.
MATERIALS AND METHODS
Chronic HFD in MIL10 mice. Male transgenic mice with muscle-specific
overexpression of IL-10 (MIL10) and wild-type (WT) littermates were fed
anHFD (55% fat by calories [Teklad TD93075; Harlan,Madison,WI]) or
standard chow diet (Prolab Isopro RMH 3000 5P75; LabDiet, St. Louis,
MO) ad libitum for 16 weeks (n  6/group). During chronic high-fat
feeding, we performed a weekly measurement of body composition to
determine the changes in whole-body fat and lean masses.
Generation of MCK-IL10ob/ob mice. We generated leptin-deficient
mice with muscle-specific overexpression of IL-10 (MCK-IL10ob/ob) by
cross-breedingMIL10micewith ob/ heterozygousmice (purchased from
the Jackson Laboratory, Bar Harbor, ME). The F1 female MCK-IL10ob/
mice were then intercrossed with male ob/ mice to generate MCK-
IL10ob/ob mice. The metabolic studies were conducted in MCK-IL10ob/ob
mice that had been backcrossed formore than five generations (ob/ob, n
7; MCK-IL10ob/ob, n 12).
Generation of M-IL10R/ mice. Mice lacking IL-10 signaling in
skeletal muscle (M-IL10R/) were generated by cross-breeding MCK-
Cre-expressing mice (kindly donated by Roger J. Davis) and floxed
IL10R1/mice (kindly donated byWernerMuller). Themetabolic stud-
ies were conducted in M-IL10R/ mice that had been backcrossed for
several generations.M-IL10R/mice andMCK-Cremice (referred to as
WT) serving as controls were fed with an HFD or standard chow diet for
6 weeks (n  6 to 11/group). All mice were housed under a controlled
temperature (23°C) and light/dark cycle with free access to food and wa-
ter. The animal studies were approved by the Institutional Animal Care
and Use Committee of the University of Massachusetts Medical School.
Body composition and energy balance. Whole-body fat and lean
masses were noninvasively measured using proton magnetic resonance
spectroscopy (1H-MRS) (Echo Medical Systems, Houston, TX). Indirect
calorimetry and energy balance parameters, including food/water intake,
energy expenditure, respiratory exchange ratio, and physical activity were
noninvasively assessed for 3 days using metabolic cages (TSE-Systems,
Inc., Bad Homburg, Germany). We used the TSE-Systems LabMaster
platform with easy-to-use calorimetry featuring fully automated moni-
toring for food and water and activity in the x, y, and z planes. LabMaster
cages that are most similar to facility home cages were used, thereby al-
lowing the use of bedding in the cage and minimizing any animal anxiety
during the experimental period. The system provides intuitive software
with flexibility for experimental setup and data utilization.
Hyperinsulinemic-euglycemic clamp experiments. Following a
standard chow diet or an HFD, survival surgery was performed at 5 to 6
days before clamp experiments to establish an indwelling catheter in the
jugular vein. On the day of the clamp experiment, mice were fasted
overnight (17 h), and a 2-h hyperinsulinemic-euglycemic clamp was
conducted in conscious mice with a primed and continuous infusion
of human insulin (priming at 150 mU/kg body weight, followed by 2.5
mU/kg/min [Humulin; Eli Lilly, IN]) (18). To maintain euglycemia,
20% glucose was infused at variable rates during the clamps. Whole-
body glucose turnover was assessed with a continuous infusion of
[3-3H]glucose (PerkinElmer, Waltham, MA), and 2-deoxy-D-[1-14C]
glucose (2-[14C]DG) (PerkinElmer, Waltham, MA) was administered
as a bolus (10 Ci) at 75 min after the start of the clamps to measure
insulin-stimulated glucose uptake in individual organs. At the end of
the clamps, mice were anesthetized, and tissues were taken for bio-
chemical analysis.
Biochemical analysis and calculation. Glucose concentrations dur-
ing the clamps were analyzed using 10 l of plasma by a glucose oxidase
method on an Analox GM9 Analyser (Analox Instruments, Ltd., London,
United Kingdom). Plasma concentrations of [3-3H]glucose, 2-[14C]DG,
and 3H2Owere determined following deproteinization of plasma samples
as previously described (18). For the determination of tissue 2-[14C]DG-
6-phosphate (2-[14C]DG-6-P) content, tissue samples were homoge-
nized, and the supernatants were subjected to an ion exchange column to
separate 2-[14C]DG-6-P from 2-[14C]DG. Plasma insulin levels were
measured using an enzyme-linked immunosorbent assay (ELISA) kit
(Alpco Diagnostics, Salem, NH). Intramuscular triglyceride concentra-
tions were determined by homogenizing muscle samples (quadriceps) in
chloroform-methanol and using a triglyceride assay kit (Sigma, St. Louis,
MO). Plasma nonesterified fatty acid (NEFA) levels were measured by an
NEFA kit (Zenbio, Durham, NC), according to the manufacturer’s pro-
tocol.
Rates of basal hepatic glucose production (HGP) and insulin-stimu-
lated whole-body glucose turnover were determined as previously de-
scribed (18). The insulin-stimulated rate of HGP was determined by sub-
tracting the glucose infusion rate from whole-body glucose turnover.
Whole-body glycolysis and glycogen plus lipid synthesis from glucose
were calculated as previously described (18). Insulin-stimulated glucose
uptake in individual tissues was assessed by determining the tissue (e.g.,
skeletal muscle) content of 2-[14C]DG-6-phosphate and the plasma
2-[14C]DG profile.
Molecular analysis for insulin signaling and inflammation. Skeletal
muscle (quadriceps) and liver samples were collected at the end of the
clamp experiments to assess insulin signaling by immunoblotting with
rabbit monoclonal antibodies against Akt and phospho-Akt-Ser473 (p-
Akt-Ser473) (Cell Signaling, Danvers, MA). Muscle samples were homog-
enized, and plasma and homogenized muscle samples were used to mea-
sure the levels of interleukin-6 (IL-6), IL-10, gamma interferon (IFN-),
and IL-1 using an enzyme-linked immunosorbent assay (ELISA) with a
Luminex 200Multiplex system (Millipore, Darmstadt, Germany). Plasma
IL-10 levels were measured using an ELISA kit (Abcam, Cambridge,
United Kingdom).
For quantitative real-time PCR (qRT-PCR), RNA isolation was per-
formed with homogenizedmuscle (gastrocnemius and quadriceps), liver,
and white adipose tissue samples using TRIzol (Life Sciences, Carlsbad,
CA) according to the manufacturer’s protocols. cDNA was synthesized
from 2 g of total RNA by use of an Omniscript cDNA synthesis kit
(Qiagen, Venlo, Netherlands). cDNA and SybrGreen supermix (Bio-Rad,
Hercules, CA) were run in a Bio-Rad-CFX96 real-time system with the
primers listed in Table S1 in the supplemental material. Relative gene
expression was calculated in comparison to the level of the housekeeping
gene.
Histologic analysis. Skeletal muscle samples (gastrocnemius) were
collected, fixed in 10% neutral formalin for 48 h, and embedded in par-
affin blocks. Sections (5 m) were taken and stained with hematoxylin-
eosin. Images were taken under a magnification of	20.
Statistical analysis. Data are expressed as means 
 standard errors
(SE). The significance of difference in mean values was determined using
two-way analysis of variance (ANOVA) with Newman-Keuls and Games-
Howell tests for post hoc analysis and Student’s t test where applicable. The
statistical significance was set at a P value of0.05.
RESULTS
Chronic feeding of anHFD inMIL10mice. Starting at 6 to 7weeks
of age, male MIL10 and WT mice were fed with a standard chow
diet or an HFD ad libitum for 16 weeks. At the end of the feeding
period, allmicewere agematched formetabolic studies.MIL10 and
WTmice showed similar body weights on the standard chow diet,
and after 16 weeks of an HFD, both groups of mice became obese
with comparable increases in body weights (Fig. 1A). Consistent
with this, whole-body fat mass, measured using 1H-MRS, was not
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different between standard-chow-fedMIL10 andWTmice, and fat
mass increased by 3- to 4-fold after anHFD in both groups ofmice
(Fig. 1B). Although whole-body lean mass was statistically differ-
ent between the groups on the standard chow diet (25.1
 0.3 g in
WTmice versus 23.5
 0.6 g in MIL10 mice; P 0.03), this differ-
ence of 1.5 g of lean mass is within the range of variability for the
leanmass of C57BL/6mice.Whole-body leanmassmeasurements
after an HFD did not differ between groups (Fig. 1C). Metabolic
cage analysis showed no significant difference in values for daily
food intake, VO2 consumption, and physical activity between
MIL10 and WT mice after 16 weeks of an HFD (see Fig. S1 in the
supplemental material).
MIL10 mice are protected from HFD-induced insulin resis-
tance. Basal glucose levels increased after 16 weeks of an HFD in
both groups of mice (i.e., hyperglycemia), and plasma insulin lev-
els were also elevated by more than 6-fold in both groups of mice
after an HFD (Fig. 1D and E). To determine the effects on whole-
body glucose metabolism, a 2-h hyperinsulinemic-euglycemic
clamp was conducted in awake mice. During the clamp, plasma
glucose levels were maintained at euglycemia (7 mM), and
plasma insulin levels were raised to 130 pM and 230 pM in
both groups of standard-chow- and HFD-fed mice, respectively
(Fig. 2A and B).
After 16 weeks of an HFD, the WT mice developed insulin
resistance, as shown by a 60% decrease in glucose infusion
rates during the clamp compared to the level in standard-
chow-fed WT mice (Fig. 2C). Although glucose infusion rates
also decreased in the MIL10 mice after an HFD, the glucose
infusion rates in the HFD-fed MIL10 mice were significantly
higher than in HFD-fed WT mice (Fig. 2C). Radioactive iso-
tope labeling data during the clamp showed a markedly in-
creased whole-body glucose turnover in the HFD-fed MIL10
mice compared to that of the HFD-fed WT mice (Fig. 2D),
indicating that MIL10mice were more insulin sensitive thanWT
mice after 16 weeks of an HFD.
Increased insulin sensitivity inHFD-fedMIL10mice was largely
due to a 30% increase in glucose uptake in skeletal muscle (quad-
riceps) (Fig. 2E). Insulin-stimulated glucose uptake in gastrocne-
mius muscle also increased in HFD-fed MIL10 mice compared to
that in HFD-fedWTmice, but this difference did not reach statis-
tical significance (Fig. 2F). To further examine muscle insulin ac-
tion, we performed Western blotting using skeletal muscle to as-
sess insulin signaling and found that Ser-473 phosphorylation of
Akt did not differ betweenWTandMIL10mice on a standard chow
diet, consistent with comparable muscle glucose uptake in these
mice (see Fig. S2A in the supplementalmaterial). After 16weeks of
an HFD, muscle Akt phosphorylation was decreased by70% in
WTmice (P 0.1), andmuscle Akt phosphorylation tended to be
higher in HFD-fed MIL10 mice than in HFD-fed WT mice (Fig.
3A). Hematoxylin-eosin-stained sections of skeletal muscle
from WT and MIL10 mice showed no obvious anomaly in the
overall structure (Fig. 3B). Additionally, intramuscular triglyc-
FIG 1 Metabolic profiles of muscle-specific IL-10-overexpressing mice (MIL10) and WT mice on standard chow and after 16 weeks of an HFD. (A) Body
weight. (B) Whole-body fat mass. (C) Whole-body lean mass. (D and E) Basal plasma glucose and insulin levels following overnight fast (17 h). Values
are means 
 SE for 6 mice in each group. *, P  0.05.
Dagdeviren et al.
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eride levels tended to be elevated in standard-chow-fed MIL10
mice compared to the levels in standard-chow-fed WT mice
(Fig. 3C). After the HFD, intramuscular triglyceride levels were
comparable between MIL10 and WT mice. The IL-10 mRNA
levels in skeletal muscle were approximately 2-fold higher in
HFD-fed MIL10 mice than in HFD-fed WT mice (Fig. 3D).
Obesity-mediated inflammation in skeletal muscle is atten-
uated in MIL10 mice. We have previously shown that inflamma-
tion develops in skeletal muscle after 3 weeks of an HFD and that
this local inflammation may be causally associated with insulin
resistance (9). To that end,we assessed the inflammation profile in
skeletal muscle by performing quantitative RT-PCR using sam-
ples obtained fromHFD-fed MIL10 andWTmice. Skeletal muscle
mRNA levels of F4/80 and CD68, as markers of macrophage infil-
tration, were decreased significantly in HFD-fedMIL10 mice com-
pared to levels in HFD-fed WT mice (Fig. 4A and B). Muscle
monocyte chemotactic protein 1 (MCP-1) mRNA levels also de-
creased inHFD-fedMIL10mice (Fig. 4C). Using Luminex analysis,
we found that local levels of IFN-, IL-1, and IL-6were increased
by 2- to 4-fold in muscle samples fromWTmice after 16 weeks of
anHFD (Fig. 4D to F). In contrast, muscle samples fromHFD-fed
MIL10mice showed completely normal levels of IFN-, IL-1, and
IL-6, indicating that muscle IL-10 overexpression protected
against diet-induced inflammation in skeletal muscle (Fig. 4D to
F). Plasma levels of IL-10 and IL-6 did not significantly differ
between WT and MIL10 mice on standard chow or an HFD (see
Fig. S2B and C in the supplemental material). Plasma IL-1 levels
tended to increase by more than 2-fold inWTmice after 16 weeks
of an HFD, but levels in MIL10 mice were not affected by an HFD
(see Fig. S2D).
Obesity-mediated inflammation and insulin resistance in
adipose tissue and liver. Insulin-stimulated glucose uptake in
white and brown adipose tissues did not differ between standard-
chow-fedWTandMIL10mice (Fig. 5A andB). After 16weeks of an
HFD,white and brown adipose tissue developed insulin resistance
in both groups of mice (Fig. 5A and B). mRNA levels of the mac-
rophage markers F4/80 and CD68 were also increased in white
adipose tissue by a chronic HFD but were not different between
HFD-fed WT and MIL10 mice (Fig. 5C and D).
Basal HGP levels did not differ betweenWT andMIL10mice on
a standard chow diet or an HFD (Fig. 6A). During the clamp,
insulin decreased HGP in both standard-chow-fedWT andMIL10
mice (Fig. 6B). HFD-fedWTmice developed insulin resistance in
liver, as indicated by increased clamp HGP, but HFD-fed MIL10
mice showed lower clampHGP thanHFD-fedWTmice (Fig. 6B).
Western blot analysis showed that neither phospho-Akt nor total
Akt protein levels were altered between WT and MIL10 mice on
standard chow or an HFD (Fig. 6C). However, liver mRNA levels
of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate
carboxykinase (PEPCK) tended to be lower in HFD-fed MIL10
mice than in HFD-fed WT mice (Fig. 6D and E). mRNA levels in
liver of the macrophage markers CD68 and F4/80 were not signif-
icantly altered in HFD-fed MIL10 mice, indicating that local in-
flammation was selectively suppressed in skeletal muscle (see Fig.
S2E and F in the supplemental material).
IL-10-expressing leptin-deficient mice are protected from
insulin resistance. Recent studies have shown deleterious ef-
fects of an HFD on the intestinal epithelium and the role of gut
microbes on obesity-mediated inflammation (19). Thus, we
have generated muscle-selective IL-10-expressing, spontane-
FIG 2 A 2-h hyperinsulinemic-euglycemic clamp was performed in awake WT and MIL10 mice after 16 weeks of an HFD to assess insulin sensitivity. (A and B)
Plasma glucose and insulin levels during the clamp. (C) Steady-state glucose infusion rates during the clamps. (D) Whole-body glucose turnover. (E and F)
Insulin-stimulated glucose uptake in skeletal muscle (quadriceps and gastrocnemius). Values are means
 SE for 6 mice in each group. *, P 0.05.
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ously obesemice by cross-breedingMIL10mice with heterozygous
leptin-deficient ob/ mice. The offspring from this cross were
further mated to obtain MCK-IL10ob/ob mice. As expected, ob/ob
mice became obese spontaneously on a standard chow diet, and
by 16 weeks of age, whole-body fat mass accounted for more
than 50% of body weight in ob/ob mice (Fig. 7A and B). MCK-
IL10ob/ob mice also became spontaneously obese on a standard
chow diet and reached a degree of obesity comparable to that of
ob/ob mice at 16 weeks of age (Fig. 7A and B). Basal plasma
glucose and fatty acid levels were similar in both groups of mice
(Fig. 7C; see also Fig. S3A in the supplemental material). A
3-day metabolic cage analysis showed that daily food intake
and physical activity did not differ between groups (Fig. 7D and
E). In contrast, MCK-IL10ob/ob mice showed a modest but sig-
nificant increase in energy expenditure that was largely due to
elevated VO2 consumption selectively in the night cycle com-
pared to levels in ob/ob mice (Fig. 7F and G).
The hyperinsulinemic-euglycemic clamp study showed a
significantly increased whole-body glucose turnover in MCK-
IL10ob/ob mice compared to that in ob/ob mice, suggesting in-
creased insulin sensitivity in these mice (Fig. 8A). Consistent with
this notion, insulin-stimulated glucose uptake in skeletal muscle
tended to increase in MCK-IL10ob/ob mice compared to that in
ob/obmice although this difference did not reach statistical signif-
icance (Fig. 8B). Glucose uptake in white adipose tissue and he-
patic insulin action did not differ between groups (Fig. 8C andD).
Mice lacking muscle IL-10 signaling are insulin resistant af-
ter an HFD. To determine the cell type responsible for the down-
stream effects of IL-10, we have generated mice with muscle-spe-
cific ablation of IL-10 receptor (M-IL10R/) (see Fig. S3B and
C).MaleM-IL10R/mice andMCK-Cremice (as controls;WT)
were fed an HFD or standard chow diet ad libitum starting at 7
weeks of age.Metabolic studies were performed after 6weeks of an
HFD, prior to the onset of overt hyperglycemia that may affect
glucose metabolism (i.e., glucose toxicity). Both groups of
M-IL10R/ andWTmice gained similar fat masses after 6 weeks
of anHFD (Fig. 9A). Basal glucose levels were higher after anHFD
in M-IL10R/ mice than in WT mice (Fig. 9B). During the hy-
perinsulinemic-euglycemic clamp, plasma glucose levels were
maintained at euglycemia (7 mM) in both groups of mice (data
not shown). Strikingly, whole-body glucose turnover rates were
significantly decreased, and glucose infusion rates were lower in
HFD-fedM-IL10R/ than inHFD-fedWTmice (Fig. 9C andD).
Hepatic insulin action during the clamp did not differ between
WT and M-IL10R/ mice fed standard chow or an HFD (Fig.
9E).Quadriceps and gastrocnemiusmuscle glucose uptake tended
to be lower in M-IL10R/ mice than in WT mice after an HFD
(see Fig. S3D in the supplemental material).
FIG 3 Insulin signaling, muscle morphology, and triglyceride and IL-10 levels in skeletal muscle. (A) Insulin-stimulated Akt phosphorylation in quadriceps
muscles. (B) Hematoxylin-eosin staining of gastrocnemiusmuscles ofMIL10 andWTmice fed standard chow or anHFD. (C) Intramuscular triglyceride content
in quadriceps muscles of MIL10 and WT mice fed standard chow or an HFD (n 3 to 5/group). (D) IL-10 mRNA levels in gastrocnemius muscles of HFD-fed
MIL10 and WT mice as measured by qRT-PCR (n 4 or 5/group). Values are means
 SE for each group. *, P 0.05. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Dagdeviren et al.
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Furthermore, local IL-10 levels in skeletal muscle tended to
decrease inM-IL10R/mice as a possible feedback loop of IL-10
signaling (see Fig. S3E). Muscle mRNA levels of F4/80 (macro-
phage marker) and tumor necrosis factor alpha (TNF-) were
markedly increased in WT mice after an HFD (Fig. 9F and G).
Importantly, HFD-fed M-IL10R/ mice showed a significant
further increase in muscle mRNA levels of F4/80, TNF-, IL-6,
and IL-1 compared to levels in HFD-fed WT mice, indicating
that muscle deletion of IL-10 receptor exacerbated HFD-induced
local inflammation in skeletal muscle (Fig. 9F to I).
FIG 4 Local inflammation in skeletal muscles of MIL10 andWTmice on standard chow or after 16 weeks of an HFD. (A to C) F4/80, CD68, andMCP-1 mRNA
levels in quadriceps muscles of HFD-fed MIL10 andWTmice as measured by qRT-PCR (n 3/group). (D to F) IFN-, IL-6, and IL-1 levels in gastrocnemius
muscles of HFD- and standard-chow-fed MIL10 and WT mice as measured by multiplex ELISA (n  4 to 6/group). Values are means 
 SE for each group. *,
P 0.05. AU, arbitrary units.
FIG 5 Insulin-stimulated glucose uptake and inflammation in adipose tissues. (A and B) Insulin-stimulated glucose uptake in white (epidydimal) and brown
(intrascapular) adipose tissue inMIL10 andWTmice fed standard chow or anHFD (n 4 to 7/group). (C andD) F4/80 and CD68mRNA levels in white adipose
tissues of MIL10 and WT mice fed standard chow or an HFD (n 5 or 6/group). Values are means
 SE for each group. *, P 0.05.
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DISCUSSION
Although adipose tissue macrophage accumulation and inflam-
mation are well-described characteristics of obesity-mediated in-
sulin resistance, recent studies refute the cause-and-effect rela-
tionship between adipose tissue inflammation and insulin
resistance (5–8). Lee et al. have shown that insulin resistance de-
velops in the absence of adipose tissue inflammation after 3 days of
high-fat feeding (8). Our recent study also found that a short-term
weight loss induced by a low-calorie diet or by exercise improves
insulin sensitivity without altering adipose tissue inflammation
(7). These findings indicate that adipose tissue inflammation de-
velops in obesity, but itmay not be causally associatedwith insulin
resistance in skeletalmuscle, amajor organ responsible for glucose
disposal.
Obesity is a state of systemic inflammation, and local inflam-
mation develops inmultiple organs, including skeletalmuscle and
liver (9, 10). Importantly, recent studies have suggested a direct
and causal role of skeletal muscle inflammation and muscle-de-
rived cytokines in the development of insulin resistance (20–25).
Our previous study has found that after 3 weeks of high-fat feed-
ing, skeletal muscle was characterized by inflammation, insulin
resistance, and reduced glucose metabolism (9). Thus, these find-
ings are consistent with a notion that an HFD-mediated local in-
flammation in skeletal muscle is causally associated with insulin
resistance. However, the metabolic and inflammatory process de-
veloping in metabolic organs after a short-term high-fat feeding
may differ from the events following chronic obesity. Addition-
ally, chronic obesity models (e.g., a long-term HFD) that are bet-
ter reflecting type 2 diabetes conditions potentially involve in-
creased insult from immune cells and inflammatory signaling in
skeletal muscle, adipose tissue, and kidney as well as more com-
promised lipid metabolism and inflammation in the liver (8, 26,
27). Therefore, our current study addresses the effects of anti-
inflammatory cytokine IL-10 under chronically obese conditions
induced by a 16-week feeding of an HFD. Moreover, leptin is
known to regulate inflammation and immunity with its effects on
T cell and macrophage-secreted cytokines (17, 28, 29). Thus, the
leptin-deficient model used in the current study rules out the po-
tential leptin effects on inflammation.Our newly generatedMCK-
IL10ob/obmice also circumvent direct effects of excess dietary lipid
uptake and lipid-induced inflammation/insulin resistance be-
cause thesemice develop spontaneous obesity on a standard chow
diet.
As a model of diet-induced obesity and type 2 diabetes, we
examined the effects of a long-term HFD on glucose metabolism
and local inflammation in MIL10 mice. After 16 weeks of an HFD,
WTmice becamemarkedly obese, with a 4-fold increase in whole-
body fatmass. Intramuscular levels of IL-6, IFN-, and IL-1were
low in chow-fed mice as expected, but after 16 weeks of an HFD,
local cytokine levels in skeletalmusclewere elevated by 3- to 4-fold
in WT mice. Some of these inflammatory cytokines may be re-
leased by locally infiltrating macrophages and/or surrounding
adipocytes in skeletal muscle fiber. IL-6 was previously shown to
induce insulin resistance by activating STAT3 and increasing in-
tracellular levels of SOCS3, which may target insulin-signaling
proteins for ubiquitin-mediated degradation, causing insulin re-
FIG6 Hepatic glucosemetabolism and insulin signaling inMIL10 andWTmice fed standard chowor anHFD for 16weeks. (A andB)Hepatic glucose production
(HGP) at the basal state and during a hyperinsulinemic-euglycemic clamp in mice (n 5 or 6/group). (C) Insulin-stimulated Akt phosphorylation in liver. (D
and E) Liver G6Pase and PEPCK mRNA levels (n 4 to 6/group). Values are means
 SE for each group. *, P 0.05.
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sistance (30, 31). In contrast, IL-6 has also been shown to be re-
leased by postexercise skeletal muscle and to promote glucoseme-
tabolism, but this cellular effect involves a much higher level of
IL-6 than what is typically observed in obesity (32). Furthermore,
IL-1 was shown to inhibit insulin signaling by inducing serine
phosphorylation of insulin receptor substrate 1 (IRS-1) in adi-
pocytes (33). Consistent with this notion, insulin-stimulated Akt
phosphorylation was reduced in the skeletal muscle of HFD-fed
FIG 7 Metabolic effects of muscle-specific IL-10 overexpression in leptin-deficient ob/ob mice (MCK-IL10ob/ob). (A to C) Body weight, whole-body fat mass
using 1H-MRS, and fasting glucose levels were measured from 7 MCK-IL10ob/ob and 11 ob/ob mice. (D to G) Daily food intake, physical activity, energy
expenditure, and average of hourly VO2 consumptionweremeasured during a 3-day analysis ofmetabolic cages in 3MCK-IL10
ob/ob and 4 ob/obmice. Values are
means
 SE for each group. *, P 0.05.
FIG 8 A 2-h hyperinsulinemic-euglycemic clamp in awake MCK-IL10ob/ob and ob/ob mice. (A) Whole-body glucose turnover in MCK-IL10ob/ob (n  7) and
ob/ob (n 11)mice. (B) Insulin-stimulated glucose uptake in gastrocnemius and quadricepsmuscles. (C)White adipose tissue glucose uptake inMCK-IL10ob/ob
(n 7) and ob/ob (n 12)mice. (D)Hepatic insulin action reflected as insulin-mediated percent suppression of HGP inMCK-IL10ob/ob (n 7) and ob/obmice
(n 11). Values are means
 SE for each group. *, P 0.05.
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WT mice, supporting the cause-and-effect relationship between
obesity-mediated increases in local macrophages and inflamma-
tory cytokines and skeletal muscle insulin resistance.
Despite marked obesity after 16 weeks of an HFD, MIL10 mice
were significantlymore insulin sensitive thanWTmice, whichwas
largely due to increased insulin signaling and glucose metabolism
in skeletal muscle. Intramuscular lipid levels were also similar be-
tween WT and MIL10 mice after an HFD, indicating that IL-10-
mediated suppression of muscle inflammation can improve insu-
lin sensitivity without altering intramuscular lipid content in
obese mice. IL-10 is an anti-inflammatory cytokine previously
known as cytokine synthesis inhibiting factor (CSIF) and pro-
duced by many immune cell types, including CD4 T helper cells
andmacrophages (34, 35). Similar to other cytokines, such as IL-6
and tumor necrosis factor alpha (TNF-), myocytes have also
been shown to express IL-10 and IL-10 receptors (9, 36). IL-10
suppresses local inflammation by inhibiting the synthesis and ac-
tion of proinflammatory cytokines, including TNF-, IL-1, and
IL-6, as well as by inhibiting macrophage activation (37, 38). To
that end, intramuscular injection of IL-10 DNA was shown to be
effective in suppressing inflammation and preventing autoim-
mune diabetes in mice (39).
Our findings that an obesity-mediated increase in IL-6, IFN-,
and IL-1 in skeletal muscle was normalized in MIL10 mice sup-
port the anti-inflammatory action of IL-10 in these mice. Also,
HFD-fed MIL10 mice had decreased levels of the macrophage
markers F4/80 andCD68, as well as reducedMCP-1mRNA levels.
Importantly, these data indicate that improved muscle glucose
metabolismmay be due to IL-10 effects to counteract local inflam-
mation in response to chronic high-fat feeding inmice. Addition-
ally, the inflammation was suppressed only in skeletal muscle of
HFD-fed MIL10 mice; there was no difference in liver and adipose
tissue inflammation levels in these mice. Plasma IL-10 levels were
also not different in HFD-fed MIL10 mice. Furthermore, in con-
trast to skeletal muscle, white and brown adipose tissues of MIL10
mice remained insulin resistant after an HFD, supporting the
muscle-specific expression of IL-10 and its effects on muscle glu-
cose metabolism. However, we found that HGP during the clamp
was significantly reduced in MIL10 mice compared to the level in
WT mice after 16 weeks of an HFD, suggesting improved hepatic
insulin action inHFD-fedMIL10mice. Since IL-10 has been shown
to be released by myocytes and since its level has been shown to
modestly increase in circulation (9), IL-10may also be responsible
for suppressing gluconeogenesis in these mice. In that regard, we
did not see alterations in liver Akt phosphorylation in HFD-fed
MIL10mice, but gluconeogenic gene expression tended to decrease
in MIL10 mice, consistent with reduced HGP in these mice.
Recent studies have shown that an HFD with selective compo-
sition of fatty acids may be directly responsible for systemic in-
flammation, possibly by altering intestinal permeability or the gut
microbe population (19). We along with others have also sug-
gested that obesity-mediated inflammation is due to excess nutri-
FIG 9 Metabolic profile, insulin action, and skeletal muscle inflammation were assessed in M-IL10R/ mice and WT mice after 6 weeks of an HFD or
standard chow diet. (A) Whole-body fat mass measured using 1H-MRS. (B) Basal glucose levels. (C) Glucose infusion rates during a hyperinsulinemic-
euglycemic clamp in awake mice (n  6 to 11). (D) Whole-body glucose turnover. (E) Hepatic insulin action expressed as insulin-mediated percent
suppression of HGP. (F to I) F4/80, TNF-, IL-1, and IL-6 mRNA levels in skeletal muscles of WT and M-IL10R/mice fed standard chow or an HFD
(n  3 to 7/group). Values are means 
 SE for each group. *, P  0.05.
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ent availability, imbalanced nutrient flux and metabolism, and
activation of intracellular endoplasmic reticulum and oxidative
stress (3, 12, 30). In order to delineate the important question
pertaining to the source of obesity-mediated inflammation, we
determined the effects of IL-10 in spontaneously obese mice by
cross-breeding MIL10 mice with leptin-deficient ob/ob mice. As
expected, IL-10-expressing ob/ob mice (MCK-IL10ob/ob) became
profoundly obese while on a standard chow diet, with a fat mass
accounting for more than 50% of their body weight. Despite
being markedly obese and having the same level of plasma free
fatty acids (FFA), MCK-IL10ob/ob mice were more insulin sen-
sitive than ob/ob mice, further demonstrating IL-10’s potent
insulin-sensitizing effects associated with its anti-inflamma-
tory effect in skeletal muscle. Thus, these data indicate that
obesity-mediated inflammation and insulin resistance in skel-
etal muscle are not dependent on dietary composition. Our
findings also suggest that IL-10’s insulin-sensitizing effects are
independent of leptin signaling.
The beneficial effects of IL-10 to protect against obesity-medi-
ated insulin resistance may be due to IL-10’s ability to suppress
local inflammation and the deleterious action of proinflammatory
cytokines in skeletal muscle. Gao et al. have recently shown that
hydrodynamic delivery of mouse IL-10 protects against the HFD-
mediated glucose intolerance that was associated with reduced
inflammation in adipose tissue (40).However, since IL-10 recep-
tors are expressed in multiple cell types, including immune
cells and myocytes (9, 41), IL-10’s direct action on myocytes
cannot be ruled out. To further determine the mechanism of
IL-10’s insulin-sensitizing effects, we generated mice with
muscle-specific ablation of IL-10 receptor. Since deletion was
specific to IL-10 receptor type 1, we excluded only IL-10 sig-
naling and not all IL-10 cytokine subfamily members. After 6
weeks of an HFD, M-IL10R/ mice became more insulin
resistant than WT mice, indicating that absence of IL-10 sig-
naling in skeletal muscle exacerbates diet-induced insulin re-
sistance. Also, mRNA levels of macrophage markers and in-
flammatory cytokines were profoundly elevated in HFD-fed
M-IL10R/mice. These results suggest that IL-10 effects may
be mediated by intracellular IL-10 signaling in skeletal muscle.
To that end, we have previously found that the obesity-induced
signal to activate local inflammation may involve oxidative
stress and altered Ca2 homeostasis in skeletal muscle (42).
Muscle IL-10 levels also tended to be lower in M-IL10R/
mice, which might be the result of a feedback mechanism.
Thus, IL-10 signaling in myocytes may relieve oxidative stress
and suppress local inflammation, resulting in improved
glucose metabolism in skeletal muscle. Further studies are
needed to understand how IL-10 may affect oxidative stress in
skeletal muscle.
In conclusion, our findings demonstrate that obesity due to
chronic high-fat feeding or leptin deficiency causes local inflam-
mation with marked increases in IL-6, IL-1, and IFN- levels in
skeletal muscle. Obesity-mediated muscle inflammation is com-
pletely attenuated by local expression of IL-10, and this anti-in-
flammatory action of IL-10 protects against muscle insulin resis-
tance. Additionally, IL-10 signaling in myocytes may relieve
obesity-induced oxidative stress and inflammation in skeletal
muscle. Taken together, these results support our previous notion
that IL-10 may be a potential therapeutic target to treat insulin
resistance and type 2 diabetes. Although IL-10 has a short half-life
in vivo, local delivery of IL-10 is safe and may have positive effects
in skeletal muscle insulin sensitivity (35). While the eventual clin-
ical application andmethod of delivery need further investigation,
the role of IL-10 as an anti-inflammatory and insulin-sensitizing
agent may open new doors in type 2 diabetes research.
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